| P2093 | author name string | Yu Chen | |
| | Bruce E Torbett | |
| | Homero Sepulveda | |
| | Sebastian Breuer | |
| | Joseph Trotter | |
| P2860 | cites work | How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease | Q27626817 |
| | A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 |
| | Human and mouse proteases: a comparative genomic approach | Q28184208 |
| | A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications | Q28213193 |
| | A guide to choosing fluorescent proteins | Q28282750 |
| | Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor | Q28368263 |
| | Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 |
| | A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism | Q28469113 |
| | Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss | Q28474984 |
| | Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells | Q29547331 |
| | Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors | Q29617995 |
| | In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors | Q29620622 |
| | Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease | Q30850215 |
| | MEROPS: the peptidase database. | Q31033155 |
| | Flow cytometric detection of proteolysis in peptide libraries synthesised on optically encoded supports. | Q33344772 |
| | Novel trends in high-throughput screening | Q33506222 |
| | Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. | Q33846032 |
| | Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response | Q34012585 |
| | Targeting proteases: successes, failures and future prospects | Q34563752 |
| | Protease inhibitors in the clinic. | Q34652378 |
| | HIV drug development: the next 25 years | Q34700544 |
| | Mechanistic considerations in high-throughput screening | Q35190730 |
| | Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. | Q35548279 |
| | Screening in a spirit haunted world | Q36515794 |
| | New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors | Q37262113 |
| | Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. | Q39579408 |
| | A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant | Q39934806 |
| | Subsite preferences of retroviral proteinases | Q40591356 |
| | Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor | Q40787173 |
| | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | Q42546287 |
| | Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. | Q44103766 |
| | A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance | Q44282271 |
| | Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens | Q44880086 |
| | Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease | Q46395635 |
| | Expression and purification of GST fusion proteins | Q46586624 |
| | Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency | Q47968734 |
| | Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Q50734050 |
| | Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy | Q73271748 |
| | High throughput flow cytometry | Q73774939 |
| | Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors | Q74220146 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4371-4381 | |
| P577 | publication date | 2011-04-27 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease | |
| P478 | volume | 50 | |